Skip to main content

Table 4 Minimal residual disease (MRD) of AJS-positive vs. AJS-negative adult patients on days 15, 29 and 79

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

Timepoint

MRD

AJS-positive (n = 5)

AJS-negative (n = 33)

p-Value (Chi-Square)

D15

< 5%

0 (0%)

22 (71%)

0.019

≥5%

4 (100%) 1 missing

9 (29%) 2 missing

D29

< 5%

0 (0%)

30 (96.8%)

< 0.001

≥5%

3 (100%) 2 missing

1 (3.2%) 2 missing

D29

< 0.1%

0 (0%)

21 (67.7%)

0.011

≥0.1%

3 (100%) 2 missing

10 (32.3%) 2 missing

D79

< 0.1%

2 (50%)

26 (89.7%)

0.120

≥0.1%

2 (50%) 1 missing

3 (10.3%) 4 missing

  1. AJS ABL-class or JAK-STAT pathway fusions, D15 Day 15, D29 Day 29, D79 Day 79m, MRD Minimal residual disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us